# Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

> **NCT05066373** · PHASE1 · COMPLETED · sponsor: **Evelo Biosciences, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Disintegration
- Healthy

## Interventions

- **DRUG:** EDP1815 capsule A
- **DRUG:** EDP1815 capsule B
- **DRUG:** EDP1815 tablet

## Key facts

- **NCT ID:** NCT05066373
- **Lead sponsor:** Evelo Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-09
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066373, "Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05066373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*